Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

5.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
5.2K
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

4.2K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
4.2K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

898
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
898
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

3.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
3.3K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

4.4K
The pathophysiology of pneumonia involves the following steps:
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Forced oscillation technique in progressive pulmonary fibrosis in a single-center retrospective study.

Scientific reports·2026
Same author

Forced oscillation technique in progressive pulmonary fibrosis in a single-center retrospective study.

Scientific reports·2025
Same author

Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users.

Journal of investigational allergology & clinical immunology·2025
Same author

Increase in Blood Eosinophil Count Over Time and Sputum IL8 are Associated with FEV<sub>1</sub> Decline in Asthma.

Lung·2024
Same author

Biologics for eosinophilic otitis media: a retrospective case study in a multidisciplinary center.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2024
Same author

Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken.

Acta clinica Belgica·2023

Related Experiment Video

Updated: Apr 15, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.4K

[Idiopathic pulmonary fibrosis].

J Guiot, J L Corhay, R Louis

    Revue Medicale De Liege
    |March 24, 2015
    PubMed
    Summary

    Idiopathic pulmonary fibrosis (IPF) is a diffuse interstitial parenchymal lung disease (IPDL). Early diagnosis of IPF is crucial for new therapies targeting pulmonary fibrosis.

    Area of Science:

    • Pulmonology
    • Radiology
    • Pathology

    Context:

    • Idiopathic pulmonary fibrosis (IPF) is a subset of diffuse interstitial parenchymal lung diseases (IPDLs).
    • IPDLs encompass approximately 200 distinct conditions, many classified as rare or orphan diseases.
    • The diagnostic landscape for IPDLs is evolving due to emerging therapeutic interventions.

    Purpose:

    • To highlight the significance of early and accurate diagnosis in the management of pulmonary fibrosis.
    • To underscore the importance of identifying IPF within the broader category of IPDLs.
    • To emphasize the clinical need for precise diagnostic tools in light of new treatment options.

    Summary:

    • Idiopathic pulmonary fibrosis (IPF) is a specific type of diffuse interstitial parenchymal lung disease (IPDL).

    More Related Videos

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    2.3K
    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
    06:29

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

    Published on: May 5, 2023

    3.3K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Refined Murine Model of Idiopathic Pulmonary Fibrosis
    07:51

    Refined Murine Model of Idiopathic Pulmonary Fibrosis

    Published on: June 17, 2025

    1.4K
    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
    06:03

    Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

    Published on: May 9, 2025

    2.3K
    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
    06:29

    Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo

    Published on: May 5, 2023

    3.3K
  • The family of IPDLs includes around 200 diseases, with many being rare.
  • Recent advancements in therapeutic options necessitate prompt and precise diagnosis of pulmonary fibrosis.

    • Impact:

    • Improved patient outcomes through timely initiation of novel IPF treatments.
    • Enhanced understanding of IPDL heterogeneity and its clinical implications.
    • Facilitation of clinical trial enrollment and drug development for rare lung diseases.